Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Multicentric reticulohistiocytosis (MRH) is a rare non-Langerhans cell histiocytosis characterized by the association of specific nodular skin lesions and destructive arthritis.
Biomarker and diagnostic research for multicentric reticulohistiocytosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for multicentric reticulohistiocytosis.
28 publications have been identified in PubMed for multicentric reticulohistiocytosis. Research spans Case Report / Case Series (57%), Other (11%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 16 | 57% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:44 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
3 |
11% |
Research summaries | 3 | 11% |
New treatment approaches | 3 | 11% |
Testing and diagnosis research | 1 | 4% |
Laboratory research | 1 | 4% |
Disease patterns and progression | 1 | 4% |
Watabe D (2026). [PMID: 42265913](https://pubmed.ncbi.nlm.nih.gov/42265913/). *J Dermatol*. [Other]
Khasnis A (2026). [PMID: 41482463](https://pubmed.ncbi.nlm.nih.gov/41482463/). *Cleveland Clinic journal of medicine*. [Review / Meta-Analysis]
Ding M (2026). [PMID: 41637085](https://pubmed.ncbi.nlm.nih.gov/41637085/). *JAMA dermatology*. [Case Report / Case Series]
Fend F (2026). [PMID: 40210741](https://pubmed.ncbi.nlm.nih.gov/40210741/). *Virchows Archiv : an international journal of pathology*. [Case Report / Case Series]
Deville-Cavellin O (2026). [PMID: 41786636](https://pubmed.ncbi.nlm.nih.gov/41786636/). *Modern rheumatology case reports*. [Case Report / Case Series]
Syyli N (2026). [PMID: 41308465](https://pubmed.ncbi.nlm.nih.gov/41308465/). *Ann Dermatol Venereol*. [Other]
Waked JAA (2026). [PMID: 41891503](https://pubmed.ncbi.nlm.nih.gov/41891503/). *J Cutan Med Surg*. [Other]
Pamfil C (2026). [PMID: 41898754](https://pubmed.ncbi.nlm.nih.gov/41898754/). *Int J Mol Sci*. [Case Report / Case Series]
Zimbric H (2026). [PMID: 42053022](https://pubmed.ncbi.nlm.nih.gov/42053022/). *J Cutan Pathol*. [Case Report / Case Series]
Hilliquin S (2026). [PMID: 42097694](https://pubmed.ncbi.nlm.nih.gov/42097694/). *RMD Open*. [Case Report / Case Series]
AI-curated news mentioning multicentric reticulohistiocytosis
Updated Jul 21, 2026
A recent study published in PubMed highlights a case of multicentric reticulohistiocytosis that progressed to erythroderma after long-term disease progression. This research adds to the understanding of disease progression in rare conditions.
A case series demonstrates successful treatment of multicentric reticulohistiocytosis using a JAK inhibitor, highlighting a potential new therapeutic approach for this rare disease. The findings contribute to the understanding of treatment options for patients with this condition.